跳至主要内容
临床试验/jRCT2080224916
jRCT2080224916已完成3 期

A Phase 3 Study in Patients with Chronic Idiopathic Thrombocytopenic Purpura in R788

Kissei Pharmaceutical Co., Ltd.1 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
24
试验地点
1
主要终点
Achievement rate of stable platelet response

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
干预模型
A Placebo-controlled, Multicenter, Randomized, Double-blind, Parallelgroup Study And A Multicenter, Open-label Study
主要目的
Treatment Purpose

入排标准

年龄范围
20age old over 至 No limit(—)
性别
All

入选标准

  • Patients diagnosed with ITP at least 6 months before acquisition of consent
  • Patients with a platelet count average of < 30000/uL during screening period and with each platelet count < 35000/uL
  • Patients who have used and failed at least 1 of the typical ITP medications before informed consent

排除标准

  • Patients with thrombocytopenia associated with other diseases
  • Patients with autoimmune hemolytic anemia
  • Patients with poor blood pressure control
  • Patients with or with a history of a history of coagulopathy

结局指标

主要结局

Achievement rate of stable platelet response

时间窗: Weeks 14 to 24

Subjects who achieve a platelet count of >= 50000/uL on at least 4 of the 6 visits from Weeks 14 to 24 are considered as a responder and the percentage of responders will be evaluated

次要结局

  • Achievement rate of overall response(Weeks 2 to 12)
  • Duration of maintained platelet count since first achievement of a platelet count >= 50000/uL after administration of the study drug
  • Achievement rate of a platelet count of >= 50000/uL at the specified evaluation time point
  • Achievement rate of a platelet count of >= 30000/uL at the specified evaluation time points and platelet count increase at least 20000/uL above baseline

研究者

研究点 (1)

Loading locations...

相似试验